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Abstract 
 
The removal of the natural vitreous body from the eye and its substitution with a tamponade agent 
may be necessary mainly in cases of complicated retinal detachment. Many materials have been 
variously proposed and tested over the years in an attempt to find an ideal vitreous substitute. This 
review highlights the evolution of the research in the field of vitreous replacement and chronicles 
the main advances that have been made in such a context. The suitability and limitations of the 
vitreous tamponade agents and substitutes in current clinical use are examined, and the promises of 
experimentally tested biomaterials are described and discussed. Future trends for the research are 
also considered; specifically, the great potential carried by polymeric hydrogels is emphasized, as 
they seem to be very effective in closely mimicking the features of the natural vitreous and they 
could successfully act as long-term vitreous substitutes without inducing clinical complications in 
the patient’s eye.  
 
Keywords: Vitreous substitution; Retinal detachment; Silicone oil; Perfluorocarbons; Polymers; 
Hydrogels. 
 
1. Introduction 
 
The substitution of the vitreous body is one of the most interesting and challenging field of research 
in ophthalmology. The surgical treatment of complicated cases of retinal detachment (RD) requires 
typically the availability of a vitreous tamponade agent able to restore the volume and internal 
pressure of the ocular globe and to approximate the detached neurosensory retina to the retinal 
pigment epithelium (RPE). Although over the years a lot of clinical and experimental work has been 
performed in order to find an appropriate vitreous substitute, at present a truly functional candidate 
for long-term use does not exist yet. The various disadvantages of the vitreous tamponade agents 
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clinically used today – sulphur hexafluoride, perfluorocarbon gases, perfluorocarbon liquids, 
silicone-based oils – led to the investigation of several alternative materials, ranging from donor 
vitreous to synthetic polymers, in the search for an ideal biomaterial that may be left safely in the 
vitreous cavity for long-term tamponade. 
This article, after giving an overview on the anatomy and physiology of the vitreous body, as well 
as on the surgical procedures adopted for its substitution, focuses on the materials that are currently 
employed in the clinical practice or experimentally tested for vitreous replacement. Their suitability, 
advantages and drawbacks are outlined and extensively discussed; particular emphasis is laid on 
polymeric insoluble gels, that are the most promising candidates for long-term vitreous 
replacement. Eventually, some methodological remarks about the need for elaborating standard 
guidelines to select potential vitreous substitutes are presented at the end of the work. 
Table 1 provides a short glossary of the medical terms that are not explained directly in the text, or 
that may result unclear or unknown to non-specialist readers.  
 
2. The vitreous body: short overview 
 
The key ocular components are shown in Fig. 1, that gives an overview on the anatomy of the eye. 
The vitreous body (corpus vitreus), often termed vitreous humour or simply vitreous, is a clear, 
transparent gel filling the posterior cavity of the eye and occupying more than two-thirds of the 
ocular volume [1-3].  
 
2.1. Vitreous embryogenesis 
 
From a developmental viewpoint, it is a common practice to distinguish between “primary” and 
“secondary” vitreous [4]. The term primary vitreous refers to a particular stage of embryonic 
development, starting at the third gestational week, in which the hyaloid artery grows into the 
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vitreous cavity from the optic nerve head towards the crystalline lens. This vascular system ramifies 
and fans out to occupy almost the whole vitreous cavity. At the end of the sixth gestational week, 
the development of the secondary vitreous (avascular vitreous) begins. Traditional theories argued 
that the primary vitreous is compressed by newly formed tissue originating near the retina and 
expanding towards the centre of the vitreous cavity; this tissue, i.e. the secondary vitreous, forms 
the definitive vitreous and remains in the eye after birth [4]. Usually, the hyaloid artery and its 
branches disappear almost completely before birth, leaving a clear central zone through the vitreous 
termed Cloquet’s canal, that would represent the area of contact between primary and secondary 
vitreous. Occasionally, the artery may not fully regress (condition called “persistent hyaloid 
artery”); more commonly, small remnants of the artery may remain and be seen sometimes as 
floaters by the patient. 
Modern theories, which were recently presented in detail by Ponsioen et al. [5], have introduced the 
concept of interactive remodeling of the vitreous: during embryonic development, the human 
vitreous body is described as a highly dynamic matrix in which the primary vitreous is gradually 
replaced by the secondary vitreous, thereby rejecting the concept of a strict spatial separation 
between the two.   
During the fourth gestational month the zonular system or “tertiary” vitreous is produced at the 
level of the developing ciliary body. The zonules are the ligaments suspending the crystalline lens 
and enabling it to change shape for near or distant vision (visual accomodation). The definition of 
tertiary vitreous is not related to a subsequent developmental stage of the secondary vitreous, but it 
was coined due to the intimate association between the zonular system (Fig. 1) and the vitreous 
body. 
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2.2. Features and functions of the vitreous 
 
In human adults the vitreous weights approximately 4 g, has a density of 1.0053-1.0089 g cm
-3
, a 
refractive index (RI) of 1.3345-1.3348 and its pH ranges within 7.0-7.4 [1-3]. The vitreous is a 
composite gel mainly composed of water (98-99 %wt.), collagen fibres (type II, V/XI, VI and IX), 
glycosaminoglycans (primarily hyaluronic acid) and other non-collagenous structural proteins 
(opticin, fibrillin), together with hyalocytes (90%) and fibroblasts (10%) near the vitreous cortex. 
Hyaluronan molecules are not uniformly distributed within the vitreous but their highest 
concentration was found in the posterior vitreous cortex [6]. Furthermore, hyaluronic acid is present 
in polydisperse populations consisting of molecules of varying hydrodynamic size, which may 
account for its viscoelastic properties [7].  
From a structural viewpoint, the vitreous is a fascinating result of natural evolution as the collagen 
fibres provide a rigid scaffold while the hyaluronan macromolecules impart shock-absorbing 
properties to the whole system. Comprehensive pictures of the supramolecular organization of the 
vitreous gel were provided elsewhere [2,3,5,8]; furthermore, a detailed overview on vitreous 
remodeling and its relation with collagen turnover was recently presented by Ponsioen et al. [5]. 
Details on the viscoelastic and mechanical properties of the human vitreous were reported by 
Zimmermann [9] and Lee et al. [10], whereas the rheological properties of the animal (porcine and 
bovine) vitreous were carefully assessed by Nickerson et al. [11]. 
From an anatomical viewpoint, to the best of the author’s knowledge the most appropriate and 
fascinating description of the vitreous body was given by Worst and co-workers, who developed the 
fascinating concept of “cisternal anatomy” of the vitreous [4,12]. 
From a functional viewpoint, the vitreous protects the surrounding structures and tissues during 
mechanical trauma, allows the circulation of metabolic solutes and nutrients throughout the eye, 
regulates the oxygen tension within the eye, contributes to maintain the shape of the ocular globe 
and keeps the crystalline lens and the retina in place.    
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2.3. Aging of the vitreous 
 
With age, the vitreous mass gradually shrinks and collapses in the course of a phenomenon called 
syneresis, that may eventually lead to posterior vitreous detachment (PVD) [13,14]. PVD is a 
degenerative process in which the vitreous cortex detaches from the retina. The collagen fibres of 
the vitreous are held apart by electrical charges but, with ageing, these repulsive charges tend to 
reduce: therefore, the fibres may clump together and the hyaluronan molecules, previously located 
around the collagen fibres, become dissociated and so they form adjacent liquid lacunae. Vitreous 
liquefaction can be considered a physiological process: in fact, some post-mortem studies have 
recently demonstrated that about 50% of the vitreous gel is liquefied in people over 80 [15,16].  
PVD may also occur earlier than normal in myopic people, as well as in patients who experienced 
cataract surgery.  
Recent researches have provided new insight about the onset, progression and traction effects of 
PVD [17]. It was observed that PVD begins in the perifoveal macula and its early stages persist 
chronically and progress slowly over months to years. Vitreous traction forces resulting from 
perifoveal PVD with vitreofoveolar adhesion may cause localized cystoid foveal thickening, which 
may eventually involve the formation of a macular hole. Epiretinal membranes develop from 
cortical vitreous remnants left on the retinal surface after PVD and play a crux role, for instance, in 
promoting RD. In general, PVD may cause problems in the retinal areas where attachment to 
vitreous is tight, since small, often horseshoe-shaped breaks in the retina can result from persistent 
tugging and tearing by the vitreous [18-20]. If the retinal hole is not repaired, the vitreous fluid can 
flow into the sub-retinal space, thereby causing RD. 
 
 
 
 7 
3. Need, search and surgical procedures for vitreous substitution 
 
Vitreous replacement is necessary if the vitreous body itself becomes dysfunctional, due to various 
pathological conditions, or in the case of the surgical treatment of complicated RDs.  
Essentially, the vitreous may become dysfunctional due to opacification, liquefaction or physical 
collapse; these pathological conditions may be caused by developmental abnormalities, various 
inflammatory diseases related to infections or retinal diseases, vitreous haemorrhage, tumours, 
diabetes or degenerative processes [20-22]. Age-related PVD may be accompanied by vitreous 
bleeding and it can predispose to RD due to the traction forces developing at the points of tight 
vitreoretinal adhesion [18-20]. Vitreous damage can be also caused by trauma or the presence of 
intraocular foreign bodies. All these conditions may result in poor vision or even blindness.  
It is necessary to stress further that an intact vitreous is essential to a healthy human eye: in fact, as 
recently highlighted by Holekamp [23], age-related vitreous alterations, such as its liquefaction, 
often accompany several ocular diseases. The vitreous gel is known to play a key role in regulating 
oxygen distribution within the eye; as the gel undergoes age-related liquefaction this function is 
impaired and the resultant elevated intraocular oxygen tension may lead to oxidative stress within 
the eye, thereby contributing to disease states such as nuclear cataract and primary open-angle 
glaucoma. 
However, the treatment of a pathological vitreous is not the most common reason for which vitreous 
substitution is necessary; in fact, it is the treatment of complicated RD cases that primarily requires 
the need for vitrectomy procedures, i.e. the full or partial replacement of the vitreous body (Fig. 2). 
Par plana vitrectomy was introduced by Machemer in the early 1970s [24]: it is generally necessary 
if the surgeon’s view of retinal break(s) is hindered by vitreous bleeding, and it is recommended in 
severe cases of RD, such as tractional RD (TRD) or RD associated with PVR; this surgical 
technique can be also combined with scleral buckling procedures. The retinal holes are sealed by 
laser photocoagulation or cryotherapy. The vitreous substitute, injected into the vitreous cavity 
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during the surgical procedure, should provide tamponade to the neurosensory retina against the RPE 
and prevent the formation of new vitreoretinal tractions, which might induce retinal re-detachment. 
In the current clinical practice, surgeons often inject a gas tamponade agent into the vitreous cavity; 
postoperatively, the gas is gradually replaced by the eye fluid, that can be considered the ideal and 
physiological vitreous substitute. In cases of RD associated with severe vitreoretinal diseases 
(PVR), however, the use of a vitreous substitute with appropriate features for prolonged 
postoperative tamponade is required.  
In uncomplicated cases of rhegmatogenous RD (RRD), pneumatic retinopexy may be also used 
(Fig. 3). This technique, introduced in 1986 by Hilton and Grizzard [25], is less complex than 
vitrectomy as it does not require vitreous removal and can be performed under local anaesthesia. 
Pneumatic retinopexy involves the injection of an expansive gas into the vitreous cavity to flatten 
the retina for allowing the sub-retinal fluid to be pumped out from beneath it. The patient’s head is 
properly positioned so that the gas bubble floats exactly to the detached area and presses against it; 
cryopexy or laser photocoagulation are used for sealing the retinal tear. The gas bubble is gradually 
absorbed by the eye while a scar forms around the retinal hole, thereby sealing it securely. The 
successful retinal reattachment rate associated to pneumatic retinopexy is over 90%, but this 
procedure can be performed only in selected cases and often repeated operations are necessary, as 
widely stressed in the literature [26]. 
Therefore, the search for suitable substitutes that can be left safely in place after vitrectomy is a 
challenging and attractive field of research in ophthalmology. As outlined by Chirila and co-
workers in two fundamental contributions to ophthalmic literature [27,28], an ideal artificial 
vitreous should fulfil a complex series of requisites; specifically it should be (i) non-toxic and 
biocompatible with the ocular tissues, (ii) clear and transparent with RI and density similar to those 
of the natural vitreous, (iii) able to maintain its light transparency postoperatively without 
undergoing opacification; (iv) biologically and chemically inert, (v) appropriately rigid to act as an 
effective tamponade agent, (vi) able to allow the transfer of metabolites, proteins and solutes, (vii) 
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preferably non-absorbable and non-biodegradable in order to be maintained in the vitreous cavity 
for a period as long as possible (ideally indefinitely), (viii) preferably hydrophilic and insoluble in 
water, (ix) injectable through a small-gauge needle, (x) able to maintain its properties after 
injection, (xi) storable and sterilizable without lacking of the above-mentioned properties.      
At present, a materials able to fulfill this complex set of requisites does not exist yet, although many 
experimentations have been carried out over the years and, as stated by Sebag [29], “the history has 
witnessed the injection of nearly ever imaginable substance into the vitreous”. One of the major 
issue concerns the ability of the potential substitute to allow the diffusion of oxygen, nutrients and 
solutes within the eye. As extensively underlined by Laude et al. [30], this function becomes 
essential for those vitrectomized patients who need intravitreal drug therapy for the treatment of 
neovascular age-related macular degeneration (AMD). 
Therefore, it is clear that the design and development of an actual suitable vitreous substitutes is a 
complex issue, and achieving this will involve close collaboration between synthetic chemists, 
materials scientists, physicists, biologists and ophthalmic surgeons.     
 
4. First attempts of vitreous replacement: vitreous transplants 
 
Chronologically, healthy animal donor vitreous was the first material used for vitreous replacement 
at the beginning of the 20
th
 century, when Deutschmann injected calf and rabbit fresh vitreous into 
human patients’ eyes [31]; later, human donor vitreous [32,33] was also used. Such agents failed as 
they induced severe inflammation in the patients’ eyes due to immunological response; 
postoperative complications such as cataract, corneal damage, glaucoma and various retinal 
diseases were also reported.  
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5. Vitreous tamponade agents currently used in the clinical practice 
 
Over the years, several materials ranging from gases to liquid agents have been found suitable to 
replace the vitreous and, therefore, used in human patients. Table 2 collects the materials in current 
use; they will be examined in detail in the following sections.  
 
5.1. Gases 
 
5.1.1. Air 
 
Air was the first gas to be injected into the eye for reattaching the neurosensory retina to the RPE: 
in 1911, Ohm [34] injected purified air into the vitreous cavity to treat a RRD case. In 1938, 
Rosengren reattached a retina by using intravitreal air injection combined with diathermy and 
drainage of sub-retinal fluid [35]. In 1969, Norton et al. highlighted the advantages of this technique 
for treating giant retinal tears [36]. Although further studies demonstrated that air is not suitable as a 
long-lasting tamponade agent due to its short residence time (few days), however since the mid 
1980s air has been successfully used in some procedures of pneumatic retinopexy [37-39]. Air has 
been also experimented in conjunction with other vitreous tamponade agents during vitrectomy 
procedures, for instance in the perfluorocarbon liquids-air exchange [20,40]. Furthermore, air can 
be used during the so-called D-ACE procedure (Drain, Air, Cryotherapy, Explant) introduced by 
McLeod and co-workers in the mid 1980s [41]. 
 
5.1.2. Sulphur hexafluoride and perfluorocarbon gases 
 
In the 1970s, intravitreal expanding gases began to be used during pars plana vitrectomy 
procedures. In 1973, Norton first experimented sulphur hexafluoride (SF6) [42] and found the 
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persistence of the gas superior to air, that has an intravitreal residence time of only a few days . In 
1980 Lincoff et al. [43] proposed the use of perfluorocarbon gases (PFCGs), consisting of a 
hydrocarbon molecule in which all the hydrogen atoms are replaced by fluorine atoms. Various 
PFCGs were proposed over the years [43-46] but, at present, C3F8 is the agent of choice [20]. In 
general, their advantages with respect to SF6 include lower required intravitreal injected volumes 
due to increased expansion and longer persistence thanks to their low solubility [45,46]. Thus, the 
use of PFCGs may result in a lower rise in initial intraocular pressure (IOP) than that evaluated with 
SF6 (acute glaucoma) because of the smaller injected volume; in addition, their increased 
persistence (from 1 week to 2 months or more depending on the specific PFCG versus 3-4 days of 
air) allows prolonged tamponade thereby promoting the formation of secure chorioretinal 
adhesions. The major drawbacks related to gases are the need for patient’s post-operative posturing 
to exert the maximum tamponade effect and the persistence of quite high IOP values that could 
result in damage to the optic nerve; furthermore, cataract formation and possible damage to ciliary 
body and retina may occur [20,47,48].  
SF6 and PFCGs have been also used in cases of RD associated to PVR [49,50], but silicone oil was 
found a more suitable tamponade agent as it led to better clinical outcomes.  
SF6/air and C3F8/air mixtures were also experimented: the duration of intraocular gas tamponade 
could be controlled
 
by varying the concentration of air and other gases. The success rate was similar 
to that obtained by using SF6 or PFCGs alone [51,52]. 
At present, SF6 and C3F8 are the gases of choice for vitreous tamponade; in addition, such gases are 
also successfully used in pneumatic retinopexy procedures [20,37,53]. Unfortunately, holes located 
in the inferior retina are not easily amenable to closure by intraocular gases [54].  
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5.1.3. Occasionally used gases 
 
In the early 1980s, Lincoff et al. tested five gases – Argon, Helium, Xenon, N2O and CO2 – in 
rabbits’ eyes to evaluate their longevity into the vitreous cavity [55]. Xenon was considered the 
most promising and it was also used in 4 human patients with successful retinal reattachment in all 
cases [56]. The major drawback related to Xenon was that it disappeared very rapidly (almost 90% 
disappeared by 3 hours postoperatively) and, therefore, it was necessary to replace the gas with 
aqueous solution to ensure an adequate tamponade effect preventing ocular hypotension.  
 
5.2. Liquids  
 
5.2.1. Physiological solutions 
 
Water [57,58] and balanced salts solutions [59] were the first liquids to be injected intravitreally for 
retinal tamponade. No relevant differences in the clinical outcomes were found in using 
physiological solutions or donor vitreous. The low viscosity and the short residence time in the 
vitreous cavity of the physiological solutions prevented an adequate tamponade effect. However, 
saline solutions are still used after the removal of other tamponade agents such as silicone oil; 
furthermore, physiological solutions are employed for intravitreal rinses that are necessary, for 
instance, to ensure a complete removal of perfluorocarbon liquids from the vitreous cavity (see the 
section 5.2.3.).  
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5.2.2. Silicone-based oils 
 
Over the years, different types of silicone oil and silicone oil derivatives have been proposed and 
investigated as vitreous substitutes. The most relevant features of these oils are summarized in 
Table 3.  
The first use of silicone oil for treating RD in humans was attempted in 1962 by Cibis, who 
encountered some difficulties in managing the oil and reported several postoperative complications 
[21]. After the development of pars plana vitrectomy in the mid 1970s, the results of the use of 
silicone oil significantly improved and its use as a long-term vitreous substitute became rather 
widespread. The features, advantages, drawbacks and indications for use of silicone-based oils for 
vitreoretinal surgery have been reviewed in detail by Giordano et al. in a fundamental treatise of 
ophthalmic literature [60]. 
Formally, silicone oils for ophthalmic use are synthetic polymers belonging to the class of 
polydimethylsiloxanes. As reported in Table 3, the viscosity of the silicone oils varies within a quite 
wide range, but the agent of choice is generally considered the 5000 cSt oil; in the mid 1990s it was 
approved by FDA for intravitreous use in the USA and, since then, is marketed worldwide. 
Today, silicone oil is usually recommended for long-term retinal support and tamponade; in the 
past, silicone oil was also used as an intraoperative tool for stabilizing the retina [61] and unrolling 
the flaps of retinal tears [62], but this use was almost abandoned since perfluorocarbon liquids, 
which exhibit a higher surface tension at the water interface, have been introduced for 
intraoperative use in the 1980s (see the section 5.2.3.). It is necessary to underline that the low 
density of silicone oil in comparison with water and aqueous solutions (Table 3) causes it to float 
upon residual vitreal fluid, which leads to a reduced or absent tamponade effect in the case of 
inferior retinal breaks. In aphakic eyes, the eye is usually filled by silicone oil up to the level of the 
pupil; surgeons must be careful to avoid overfilling and the ANDO iridectomy can be helpful to 
prevent the pupillary block, the migration of the oil in the anterior chamber of the eye and the 
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development of postoperative glaucoma, kerathopathy and other complications [63-65]. Many 
studies have suggested the use of silicone oil as the preferred choice in the case of long-standing 
RRD, TRD, giant retinal tears and RD caused by proliferative diabetic retinopathy (PDR) [66-81]. 
In addition, silicone oil is usually employed in the first surgical procedure in patients unable to 
position for gases, with need to air travel immediately after surgery [82] or suffering from AIDS 
and related retinal complications [83,84].  
Although in most cases silicone oil is well-tolerated by ocular tissues, its use in vitreoretinal surgery 
has been repeatedly castigated, and the controversy about its actual suitability as a long-term 
vitreous substitute still lingers on. On one hand, silicone oil is a very promising candidate for 
prolonged vitreous substitution as it can be retained indefinitely in the vitreous cavity without 
loosing its optical transparency and chemical inertness; in addition, it can provide extended retinal 
tamponade and is considered to prevent postoperative iris neovascularisation [74,79,82,85,86]. On 
the other hand, however, there is convincing evidence that silicone oil can induce severe long-term 
complications in the patient’s eye, such as glaucoma, cataract, corneal damage and the so-called 
“silicone retinopathy” [60,87,88]. In these cases the surgical removal of the silicone oil is necessary, 
but any remaining amount might be retained indefinitely in the eye. Retinal re-detachment may also 
occur after the removal of silicone oil [89]. In the last two decades, the incidence of the various 
complications has been progressively reduced by the improvement of oil purification technologies 
(the residual components of polymerization reactions were demonstrated to be toxic [90]), the 
advances in surgical techniques and the possibility of treating successfully most of these 
postoperative diseases. Several evidences have suggested that the main cause of the above-
mentioned complications is not an intrinsic oil toxicity – which is a typical feature of the low 
molecular weight monomers and polymerization residues [90] – but an abnormal cells behaviour 
caused by the emulsification and dispersion of the silicone oil [91,92]. In fact, the cells in contact 
with the oil may incorporate silicone vesicles, whose presence can interfere with the transport of 
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metabolites. The emulsification rate, being related to fluid viscosity, can be successfully reduced by 
employing oils with viscosity higher than 5000 cSt.  
Therefore, although silicone oil exhibits very suitable properties for vitreous substitution, it should 
be used in very critical or desperate cases, preferably for temporary vitreous replacement and, in 
general, only when the other surgical procedures showed to be unsuccessful. 
Besides the silicone oil, it is necessary to mention the use of other two silicone-based oil, i.e. 
poly(methyl-3,3,3-trifluoropropylsiloxane) (fluorosilicone oil) and poly(methyl-3,3,3-
trifluoropropylsiloxane-co-dimethylsiloxane) (silicone/fluorosilicone copolymer oil), that are often 
referred to as second-generation silicone oils. 
Fluorosilicone oil exhibits properties similar to those of silicone oil, but has a higher emulsification 
rate and a lower intraocular tolerance: in fact, complications that have been associated with silicone 
oil also occur with fluorosilicone oil, but within a shorter time period [92-94]. Fluorosilicone oil, 
being heavier than water (Table 3), was used to flatten the retina intraoperatively with the patient in 
prone position for displacing the sub-retinal fluid thanks to the difference of density. In addition, 
fluorosilicone oil was successfully used for extended tamponade of inferior retinal breaks [93,94].     
Silicone/fluorosilicone copolymer oil is a polysiloxane derivative that was investigated especially 
by Refojo’s group [95,96]. It was used for the intraoperative fixation of the retina, for short-term 
vitreous substitution and as a vehicle for the intravitreal release of drugs preventing PVR [95-97]. 
Likewise fluorosilicone oil, silicone/fluorosilicone copolymer oil is heavier than silicone oil (Table 
3) and, therefore, can be successfully used in cases of inferiorly or posteriorly located retinal breaks. 
In comparison with silicone oil, silicone/fluorosilicone copolymer oil has a lower viscosity (Table 
3), which facilitates the oil injection into the eye, as well as its removal. The use of 
silicone/fluorosilicone copolymer oil for prolonged vitreous substitution induced unwanted side 
effects similar or more serious to those observed in presence of perfluorocarbon liquids (see the 
section 5.2.3.). Doi et al. injected silicone/fluorosilicone copolymer oil into rabbits eyes [96]; after 
6 months of retinal tamponade, they found the disappearance of the outer plexiform layer and the 
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disorganization of the photoreceptor layer. Therefore, the authors suggested the use of 
silicone/fluorosilicone copolymer oil only as an intraoperative tool or for short-term retinal 
tamponade (< 2 months) [96]. 
Finally, it is interesting to mention a clever approach suggested by Dailey et al. [98], who attempted 
to overcome the problem of poor surface tension by using magnetic silicone-based fluid as a 
vitreous substitute coupled with a magnetic band (scleral buckle) around the eye. The magnetic 
field resulting from the scleral buckle would contribute to maintain the vitreous substitute, in which 
metal nanoparticles were dispersed, in contact with the retina. However, it can not ignored that 
magnetic iron, cobalt, nickel and rare-earth metals are all potentially toxic to ocular tissues. 
Therefore, the toxicity of constituents and the possible removal of the buckle after successful retinal 
reattachment are crux issues that should be carefully taken into account in future studies.  
 
5.2.3. Perfluorocarbon liquids 
 
Perfluorocarbon liquids (PFCLs) are colourless and odourless; the most relevant properties of the 
three PFCLs marketed for vitrectomy procedures are reported in Table 4. The first use of PFCLs for 
vitreous substitution was reported in 1984 by Miyamoto et al., who injected perfluoroether in rabbit 
eyes; however, this tamponade agent was deemed unsuitable as a long-term vitreous substitute as it 
induced the formation of preretinal membranes, retinal disorganization and eventual RD after 
remaining in the vitreous cavity from 4 to 6 months [99]. Chang et al. tested perfluorotributylamine 
as a long-term vitreous substitute in rabbit eyes and also found unwanted side effects such as retinal 
disorganization and cells deposition in the vitreous cortex and in the posterior crystalline lens [100]. 
Therefore, researchers’ attention was drawn by the use of PFCLs only as intraoperative tools. In 
1988 PFCLs were first used in human eyes as an adjunct in the management of RDs associated with 
PVR [101]. Since then, PFCLs have been successfully employed in the intraoperative management 
of RRDs complicated by PVR [102-104] and giant retinal tears [105-107], and TRD in PDR 
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[108,109]; in addition, they were also used as short-term postoperative vitreous substitutes in 
particularly complicated RD cases [110,111]. PFCLs were also successfully used in the 
management of suprachoroidal haemorrhages [112]. 
It is important to further stress that PFCLs should not be used for prolonged vitreous substitution. 
As already mentioned, the early experimental studies in rabbits where PFCLs were used for long-
term vitreous substitution showed the occurrence of severe complications [99,100]. However, if 
PFCLs were removed from 2 to 4 days after instillation, no significant side effects were observed; 
for instance, no morphological changes in the retina were observed in animal models by using pigs 
[113] and monkeys [114]. The use of PFCLs in human eyes, thanks to the development of 
appropriate surgical procedures, has generally led to few postoperative complications; if PFCLs are 
used as short-term postoperative tamponade agents, unfortunately a second operation for their 
removal is unavoidable for the patient. 
There have been some case reports in which retinal damage has been attributed to intravitreal [115-
117] or sub-retinal retention [118-121] of PFCLs both in animal models and in humans. In fact, in 
spite of an apparently adequate removal of PFCL at the end of the surgical procedure, PFCL 
bubbles may remain in the vitreous cavity postoperatively. Residual PFCL can be detected, for 
instance, by ophthalmic ultrasound analysis; patients with remaining intravitreal PFCL must be 
carefully monitored to detect any sign of retinal toxicity, and an additional procedure should be 
performed to remove the residual PFCL bubbles. In presence of RRD with severe PVR or TRD 
with massive proliferation, the penetration of PFCL into the sub-retinal space may be an additional 
risk, especially with large retinotomies [121]; in that case, a careful PFCL-air or PFCL-
physiological solution exchange must be performed, as well as drainage/active aspiration through 
the same retinotomy or trough an additional one.  
The postoperative complications related to PFCLs seem to be due to their high density (Table 4), 
resulting in mechanical damage to cells through compression and extensive emulsification, rather 
than to an intrinsic toxicity of the material [122]. In addition to retinal damage, other reported 
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complications include postoperative glaucoma due to retained intravitreal PFCL in human eyes 
[116,120] and corneal toxicity (loss of endothelial cells, stromal inflammation, neovascularisation) 
in aphakic rabbit eyes [115].  
Weinberger et al. also reported the case of seven patients with PFCL droplets in the anterior 
chamber; after a 9-month follow-up, however, no signs of corneal damage or intraocular toxicity 
were detected [123].             
 
5.2.4. Semifluorinated alkanes and heavy oils 
 
The use of semifluorinated alkanes (SFAs) in vitreoretinal surgery is relatively new. Many 
evidences seem to indicate that SFAs can offer the potential to act as long-term vitreous substitutes. 
These materials consist of short alkyl chains joined at one end or both ends to a perfluorocarbon 
chain, thereby corresponding to the general formulas F(CF2)n(CH2)mH and F(CF2)n(CH2)m(CF2)nF 
(n, m = 3-20 in both cases), respectively. SFAs are colourless (RI ~1.3), immiscible with water and 
physically, chemically, physiologically inert [124]. Generally, SFAs are less viscous (kinematic 
viscosity ~2.5 cSt) than the other currently used intravitreal materials (Table 3 and Table 4); in 
addition, they can be more easily handled than silicone-based oils and their density (1.1-1.7 g cm
-3
) 
is lower than that of PFCLs [124-126]. SFAs are approved for clinical use in Europe and they are 
mainly marketed as biocompatible solvents for silicone oil; in addition, it was demonstrated that 
SFAs can be successfully used as such as intraoperative tools for unfolding and reattaching the 
retina [127,128] and as long-term vitreous tamponade agents [129,130]. Optically clear mixtures of 
silicone oil and SFAs (the so-called “heavy oils” or third-generation silicone oils), with typical 
density ranging within 1.0-1.3 g cm
-3
, have been also successfully tested in the treatment of 
complicated RD cases (Table 5). For instance, Densiron-68
®
 was recently found to be safe and 
effective both in the treatment of primary inferior RRD cases [131] and in the reoperation of 
persisting macular holes [132]. Long-term tamponade by using this heavy oil resulted in a high 
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anatomic success and was generally accompanied by a functional improvement of patients’ visual 
acuity [131-134] and mild postoperative complications [135]. Also the recently experimented HWS 
46-3000 was well tolerated by ocular tissue and its use was accompanied by a high rate of success 
in treating complicated RD cases [136]. On the contrary, Oxane HD was found unsuitable for 
clinical use due to the relevant incidence of adverse effects including oil emulsification, glaucoma 
and cataract [137-139]. A comprehensive review about the use of heavy oils in vitreoretinal surgery 
was recently published by Heimann et al. [140]. 
Furthermore, Meinert et al. underlined that SFAs carry the great potential of acting as solvents for 
intravitreal drugs that could be released in situ postoperatively [126].  
There are many reasonable evidences that both SFAs as such and, particularly, some heavy oils can 
be considered very promising candidates for long-term vitreous substitution thanks to their 
attractive characteristics, including good retinal tolerance [141] and reduced emulsification with 
respect to silicone oil [142]. At least ideally, they could successfully replace the agents currently 
adopted for vitreous substitution, but they are not in common use yet. 
 
6. Towards an ideal artificial vitreous: polymers mimicking the features of natural vitreous 
 
The drawbacks and limitations related to the currently used vitreous substitutes have led to the 
investigation of a wide variety of materials in the search for an ideal artificial vitreous. Table 6 lists 
the various candidates that have been experimentally proposed from the mid 1950s up to now: to 
the best of the author’s knowledge, none of them has been approved for clinical use. 
According to the author’s view, the researchers have essentially tried to duplicate the natural 
vitreous by following two approaches: (i) bio-mimicry of the chemical composition of the natural 
vitreous, in an attempt to reproduce its structure and properties; (ii) bio-mimicry of the peculiar 
features of the natural vitreous, rather than its composition or structure. The final aim was to find an 
appropriate biomaterial to be left in situ safely and indefinitely without undergoing degradation 
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and/or losing its physico-mechanical features. The first approach, involving the use of modified 
natural polymers, substantially failed: some potential substitutes for short-term use have been 
suggested, but the various studies have demonstrated that is impossible to duplicate Nature and to 
make up a “natural” vitreous artificially. Therefore, the researchers’ attention has been 
progressively drawn by synthetic polymers, that are chemically different from natural vitreous but 
are potentially able to mimic its physico-mechanical properties. 
The following sections give an overview about the potential vitreous substitutes tested in both 
approaches. In the mid 1990s, Chirila and co-workers extensively reviewed the early attempts of 
vitreous replacement by using hydrophilic polymers [27,28], and in 2000 Colthurst et al. [143] gave 
an overview on new advances; more recently, part of a review on the biomaterials used in the 
treatment of RD was dedicated to this topic, but such a work was still incomplete [144]. The history 
and performances of experimental polymers are now exhaustively reviewed, and the advances of 
the last decade, as well as the promises for the future, are particularly highlighted. 
 
6.1. First approach: compositional/structural bio-mimicry 
 
6.1.1. Hyaluronic acid 
 
Hyaluronic acid and its derivatives, such as sodium hyaluronate, have been widely tested as vitreous 
substitutes in humans since the early 1960s [145]. The choice of hyaluronic acid seemed rather 
reasonable as it is one of the two major components – together with collagen – of the natural 
vitreous. Sodium hyaluronate is commercially available in a wide range of solutions for 
pharmaceutical use, and it showed an excellent biocompatibility and tolerance in ocular tissues. 
However, these solutions were found unsuitable for prolonged postoperative vitreous tamponade 
due to their short residence time in the vitreous cavity [146].  
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6.1.2. Gelatin and collagen 
 
Gelatin is a collagen derivative marketed worldwide in various forms. Such as hyaluronic acid, the 
use of this material was suggested by the fact that collagen is present in the composition of natural 
vitreous.  
In 1966, Oosterhuis and co-workers implanted polygeline, a polymer of urea and polypeptides 
derived from degraded gelatin, in rabbits’ eyes [147]. Further studies in humans [148] showed that 
the material (RI = 1.3390, Mw = 35 kDa) was well-tolerated in all cases without adverse tissue 
reactions and the immediate retinal reattachment was achieved in most of the patients. However, 
polygeline exhibited a short retention time in the vitreous cavity and a rapid decrease of its 
viscosity. The attempts to increase the material viscosity by adding gelatin, agar, methylcellulose 
and poly(ethylene glycol) caused inflammation in ocular tissues and vitreous opacification. 
Therefore, polygeline was deemed suitable only as a short-time vitreous substitute. Despite the 
good biocompatibility and optical properties, there has been no other studies about the ocular use of 
polygeline. 
 In the last 1960s proctase-treated collagen gel was also tested for vitreous replacement in animal 
models. Studies in rabbits by Stenzel et al. [149] and in monkeys by Dunn et al. [150] showed that 
collagen did not elicit adverse effects in ocular tissues except for a mild transient inflammation.  
In the early 1970s, Pruett and co-workers tested collagen gels in human patients [151,152]: a 
moderate inflammation of ocular tissues was reported, together with other severe complications 
related to clinical outcomes; only 19% of the cases exhibited retinal reattachment and all patients 
had blurred vision due to vitreous opacification. In addition the gel underwent fragmentation during 
injection, thereby decreasing its mechanical properties.  
More recently, some of these drawbacks were overcome by using methylated type I/III collagen 
[153,154]. After material implantation in rabbits’ eye, no inflammation and no vitreous/lens/cornea 
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opacification were detected; however, the poor tamponade effect due to low surface tension made 
this polymer unsuitable for RD treatment. 
 
6.1.3. Hyaluronate/collagen gel mixture 
 
A special mention should be dedicated to the so-called “reconstituted vitreous”, a mixture of 
sodium hyaluronate and collagen that are the two major structural components of the vitreous body. 
The basic idea, proposed in the 1960s by Balazs et al. [155], was very fascinating since the 
researchers’ aim was to mimic Nature by duplicating both the composition and the structure of the 
natural vitreous. After injection at low temperature (~10 °C) the mixture underwent gelification in 
situ at body temperature. However, in vivo studies revealed problems of gel hazing during 
postoperative follow-up and, occasionally, ocular tissue inflammation; in addition, the material was 
completely bioabsorbed within 5 months after implantation. 
More recently, Nakagawa et al. injected different formulations of hyaluronate/collagen gels into 
rabbits eyes [153]; however, these gels were not considered suitable for long-term vitreous 
substitution due to their water solubility and, therefore, their tendency to become viscous solutions 
rather than gels over time, thereby producing a poor tamponade effect on the retina.  
 
6.1.4. Hyaluronic acid/gellan gum gel 
 
In 2006, Suri et al. suggested the use of a mixture of hyaluronic acid and gellan gum for vitreous 
replacement [156]. Gellan gum formed a gel at room temperature and the gel structure was 
maintained also at the body temperature. In vitro cytotoxicity tests by using mouse fibroblast cells 
showed an excellent biocompatibility (cells viability > 90%). However, the rheological and 
mechanical properties were found dramatically insufficient with respect to those of natural vitreous. 
An attempt to improve the mechanical properties of the gel was also done by adding CaCl2 to the 
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gellan gum/HA mixture in order to obtain a highly cross-linked hydrogel, but further studies are 
necessary. However, the gel does not seem suitable for long-term tamponade as it degrades after 1 
week of soaking in simulated body fluids. 
 
6.1.5. Occasionally tested polysaccharides 
 
Various solutions of different polysaccharides, e.g. dextran, dextran sulphate, sodium alginate, 
alginic acid and chondroitin sulphate, were occasionally tested as vitreous substitutes in animal 
models and humans [157,158]. No or mild inflammation was usually reported, but often the 
vitreous underwent hazing and the materials failed to reattach the retina due to their poor 
tamponade effect. 
 
6.2. Second approach: functional bio-mimicry 
 
6.2.1. Poly(1-vinyl-2-pyrrolidone) 
 
Chronologically, poly(1-vinyl-2-pyrrolidone) (PVP) was the first synthetic polymer to be tested as a 
potential vitreous substitute. In 1954, Scuderi [159] injected variable amounts of PVP solutions in 
rabbits’ eyes; no histological adverse reaction was reported, but problems of opacification occurred. 
In 1959, Hayano and Hoshino tested PVP solutions with different dilution rates in human eyes with 
RRD [160]: PVP induced less inflammatory reactions than physiological solutions but no data 
about polymer retention in the vitreous cavity were reported. No other studies about the use of PVP 
solutions are available in the literature.  
More recently, Chirila and co-workers performed a careful selection of PVP gels on the basis of 
their viscoelastic properties; eventually, the 1-vinyl-2-pyrrolidone (VP) monomer was polymerized 
with divynil glycol (DVG) as cross-linking agent to obtain a transparent (RI = 1.3390) hydrogel 
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with density and viscosity very similar to those of human vitreous [161,162]. The cross-linked PVP 
was implanted in rabbits’ eyes: no damage to the retina was detected, but vitreous opacification 
occurred; in addition, the polymer underwent biodegradation due to phagocytosis [163]. VP was 
also copolymerized with 2-hydroxyethyl methacrylate (HEMA) using DVG or diallyl ether (DAE) 
as cross-linking agents and the so-obtained hydrogel was implanted in rabbits’ eyes [164]. The 
resulting gel was clear, transparent, insoluble in water and exhibited mechanical properties close to 
those of natural vitreous. From a clinical viewpoint, no adverse effects were detected after 
implantation, except for transient vitreous opacities. However, the process of injection via a small-
gauge needle caused polymer fragmentation resulting in a decrease in the hydrogel mechanical 
properties. Furthermore, all eyes were characterized by the presence of inflammatory cells and 
vacuoles containing granular material, which indicates that material underwent phagocytosis [163].  
Dalton et al. performed a detailed study on selected cross-linked PVP-based polymers and 
suggested that rheological analysis can provide useful eliminatory criteria in the selection of 
potential vitreous substitutes [165]. 
 
6.2.2. Polyacrylamide 
 
Although acrylamide as such is highly toxic, after complete polymerization the resulting polymer 
exhibits a good biocompatibility; obviously, the presence of residual monomer can have dramatic 
effects in vivo on patients’ health.  
In 1968, Muller-Jensen et al. [166] reported several clinical trials concerning the use of 
polyacrilamide (PAA) as a vitreous substitute in rabbits’ eyes. The monomers were polymerized 
directly inside the vitreous cavity without using cross-linking agents: irritation was observed in all 
cases in the course of the first postoperative days and the vitreous underwent opacification at high 
PAA concentrations; however, no histological degeneration was observed within 3 months after 
implantation. Cross-linked PAA was also implanted in rabbits’ eyes after in situ polymerization 
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with better clinical outcomes [167]: the material was well-tolerated by tissues and remained clear 
after 14 months from implantation. In 1973, Refojo et al. [168] reported a detailed investigation 
about the optical properties of cross-linked PAA. 
For many years, no further study performed about the use of PAA as potential vitreous substitute; in 
the mid 2000s, acrylamide and bisacryloylcistamine (BAC) were copolymerized with disulfide 
cross-linking agents by Ravi and co-workers [169-173]. The use of disulfide cross-linkers allowed 
to obtain a high purification of the final polymer by removing all the residual monomers. Two 
procedures are possible for implantations: the gels can be formed directly in the eye, or else the 
final polymer can be injected into the vitreous cavity without undergoing fragmentation or loss of 
elasticity and mechanical properties, as demonstrated by preliminary tests carried out by using 
cadaver human eyes or ex vivo porcine eyes as recipients [169,173]. Furthermore, in vitro tests 
showed that the biocompatibility of the gel can be further improved by adding N-phenylacrylamide 
(hydrophobic monomer) [170]. These promising results justify further investigations about the 
suitability of PAA as artificial vitreous. 
 
6.2.3. Poly(glyceryl methacrylate) 
 
In 1968, Refojo and co-workers first used poly(glyceryl methacrylate) (PGMA) as a vitreous 
substitute [174]. Spherical pieces of dehydrated PGMA were implanted in rabbits’ vitreous cavities 
through a small surgical incision and the implants swelled in situ after contact with vitreous fluids, 
thereby reaching postoperatively volumes up to 32 times greater than the initial ones in the dry 
state. The hydrogel was found highly biocompatible (no inflammations or clinical complications 
were detected), but PGMA was eventually considered unsuitable for clinical use as its implantation 
was too traumatic; furthermore, its swelling was too slow, thereby causing problems of immediate 
tamponade.  
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In 1976, Hogen-Esch et al. synthesized an injectable PGMA hydrogel using very low amounts of 
cross-linking agents [175]. The gel was able to absorb up to 96%wt. of saline solution and, after 
swelling remained soft and sufficiently transparent. Although a slight loss of light transmittance was 
assessed, the final RI (1.3364) was still very close to that of natural vitreous. After implantation in 
rabbits’ eyes, good clinical outcomes without complications were observed; however, as the 
hydrogel underwent fragmentation upon injection, no further studies were carried out on PGMA as 
a vitreous substitute. 
 
6.2.4. Poly(2-hydroxyethyl methacrylate) 
 
In the early 1970s Refojo implanted poly(2-hydroxyethyl methacrylate) (PHEMA) solid pieces in 
rabbits’ eyes [176]. PHEMA was well-tolerated by ocular tissues, did not elicit retinal damages and 
did not undergo bioabsorption or biodegradation. It was insoluble in water and, being solid, could 
maintain its position postoperatively in the vitreous cavity better than a liquid agent. However, its 
implantation required difficult and often too traumatic surgical procedures and, therefore, it was no 
longer investigated. 
 
6.2.5. Poly(2-hydroxyethyl acrylate) 
 
In the early 1980s Chan et al. tested poly(2-hydroxyethyl acrylate) (PHEA) as a potential vitreous 
substitute in rabbits’ eyes [177]. The hydrogel exhibited excellent physical properties, such as high 
transparency, viscosity similar to that of natural vitreous, non-absorbability and easy injectability, 
which made it, also theoretically, an ideal artificial vitreous. However, some adverse effects were 
reported: in fact, PHEA induced corneal oedema, glaucoma, damage to the lens as well as its 
opacification, formation of fibrous membranes in the vitreous cavity and severe retinal 
complications. Therefore, the material was considered unsuitable for clinical use. 
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6.2.6. Hydroxypropyl methylcellulose 
 
In 1990, Fernandez-Vigo et al. injected a solution of hydroxypropyl methylcellulose (HPMC) 
(viscosity ~6000 cSt, Mw = 86 kDa) in rabbits’ eyes [178]: HPMC was completely eliminated from 
the vitreous cavity within 10 weeks after implantation and, therefore, HPMC solutions were deemed 
unsuitable both for long-term vitreous replacement and for sealing retinal holes in RRD due to the 
lacking of tamponade effect. However, the excellent biocompatibility of HPMC encourage the same 
research group to perform another animal study in which they demonstrated that it was possible to 
control and tailor the residence time of HPMC in the vitreous cavity by varying its molecular 
weight [179]. Specifically, by using a product with Mw = 120 kDa and viscosity ~6000 cSt the half-
life time of the substitute was 38 days; nonetheless, such a substitute was still unsuitable for 
prolonged tamponade.   
 
6.2.7. Pluronic F127 
 
Pluronic F127 (P-F127) solutions at concentration of 20%wt. and above show thermoreversible 
gelation behaviour [180]: for instance, a 20%wt. P-F127 solution is liquid when cold, but forms a 
clear gel (RI = 1.032) at 21°C as the solution is heated. In spite of their attractive physical 
properties, P-F127 solutions were found to be unsuitable for vitreous substitution: in fact, in 1990 
Davidorf et al. [181] showed that the polymer can induce severe retinal toxicity and, therefore, it 
was considered unsuitable for clinical use.  
 
6.2.8. Poly(vinyl alcohol) 
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In 1991, Benlian et al. first selected poly(vinyl alcohol) (PVA) as a potential vitreous substitute on 
the basis of its optical properties [182]. The preliminary results after implantation in rabbits’ eyes 
were promising, as no inflammation or damage to the retina was detected after 2 months of follow-
up. 
In 1991 Yamauchi et al. [183] also reported an extensive investigation on autoclave-sterilized PVA 
hydrogels consisting of 99%wt. of water. The gels were produced by γ-irradiation of a 7%wt. PVA 
solution and then injected into rabbits’ eyes; a comparison of performance with respect to saline 
solution was also reported. Inflammation and long-term vitreous opacification occurred more 
frequently with PVA than with physiological solutions. The short-time optical properties were 
excellent, as the gels were indistinguishable from the host vitreous during the first postoperative 
weeks. A mixture of PVA/chondroitin sulphate was also experimented: it displayed a transparency 
superior to that of PVA as such and absorbed more water than PVA alone, but it was found less 
biocompatible in rabbits’ eyes.  
In 2006, Maruoka et al. [184] prepared PVA hydrogels by treating the polymer solution in 
autoclave before γ-irradiation and injected the so-obtained gels into monkeys’ eyes. During the first 
postoperative weeks, ocular inflammation and IOP increase occurred; after 3 months of 
implantation the eyes regained normal IOP and retinal activity.  
In 2010, Leone et al. synthesized PVA hydrogels using different amounts of trisodium 
trimetaphosphate (TSTMP) as cross-linking agent [185]. The authors performed a very 
comprehensive characterization of the materials, including light transmittance, water content 
assessment, rheological measurements (oscillatory shear stress analysis, shear creep analysis and 
thixotropic properties) and in vitro cytotoxicity assays; in addition, the diffusion behaviour of the 
hydrogel by using a model solute was assessed. All these tests seemed to show that the hydrogel 
with molar ratio TSTMP/PVA = 1 : 8 fulfilled the requirements for a good vitreous substitute.   
Due to their good optical properties, rheological features and long-term biocompatibility PVA 
hydrogels are promising candidates for vitreous substitution, but further studies need to be 
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performed to collect more data about their retention time, mechanical properties and ability to 
reattach the retina. 
 
6.2.9. Silicone gel 
 
In 1992, Peyman et al. [186] injected silicone gel in monkeys’ eyes; specifically, two polymer 
formulations – clear and cloudy gels – were tested. The liquid monomers were injected into the 
vitreous cavities and polymerization occurred in situ. Apart from a minimal inflammation lasting 
for 1 week postoperatively, no other adverse effects were reported. No retinal damage was detected, 
both gels maintained their cohesiveness and, specifically, the clear gel remained transparent 
postoperatively. However, silicone gels were hydrophobic: therefore, they exerted a very poor 
tamponade effect on the retina remaining separated from it. Therefore, silicone gels were deemed 
unsuitable for the treatment of RD cases. 
 
6.2.10. Poly(methyl 2-acrylamidoglycolate methyl ether) 
 
In 1995, Chirila et al. performed a careful selection among several polymers derived from (methyl 
2-acrylamidoglycolate methyl ether) as potential vitreous substitute [187]. Eventually, the 
homopolymer poly(methyl 2-acrylamidoglycolate methyl ether) (PMAGME), synthesized in 
80%wt. of water and without cross-linking agents, was selected for in vivo tests in rabbits. 
Negligible fragmentation upon injection was observed, but severe postoperative clinical 
complications were reported, including RD, inflammation and damage to the optic nerve. The cause 
of the toxic effect remained unclear, as it could be due to the polymer itself or, maybe more 
reasonably, to residual toxic acrylamide. The authors first reported the results of in vitro studies 
using mouse fibroblast cells, that revealed the cytostatic and cytocidal effect of the hydrogel [187]. 
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For the first time, in vitro cytotoxicity assay was suggested as an important criterion for preliminary 
selection of biomaterials as potential vitreous substitutes. 
 
6.2.11. Adcon
®
-L hydrogel 
 
In 2000, De Jong et al. [188] reported in one study the use of Adcon
®
-L hydrogel for vitreous 
substitution in the right eye of 5 rabbits. Adcon
®
-L hydrogel – a polymer of proteoglycans esters in 
porcine gelatin – is highly biocompatible and it is currently used in neurosurgery without unwanted 
side effects. However, this materials was found unsuitable as a vitreous substitute, as severe 
postoperative complications were reported. In fact, the obtained results suggested a potential retinal 
toxicity of this hydrogel, as well as  such as an important and persistent postoperative inflammation 
reaction. Other reported complications were cornea opacification in 2 rabbits and cataract in all 
rabbits; in addition, the biodegradation rate of the hydrogel was rather fast and it had totally 
disappeared from the vitreous cavity  after 3 weeks. 
 
6.2.12. Poly(vinyl alcohol methacrylate) 
 
In 2004, Cavalieri et al. [189] carried out preliminary investigations on poly(vinyl alcohol 
methacrylate) (PVA-MA) to test its potential suitability as a vitreous substitute. The polymer 
contained a photoinitiator and the gel network could be formed by irradiation at 365 nm; the degree 
of cross-linking could be tailored by varying the photoinitiator concentration and the radiation 
exposure time. PVA-MA was found able to gel in situ; specifically, gelification did not occur at 
polymer concentrations lower than 4%wt. In vitro tests by using bovine serum showed that 
hydrogel degradation occurred in presence of a low cross-linking degree. Therefore, potentially 
suitable PVA-MA hydrogels were deemed to be those synthesized at high polymer concentrations 
and with a high degree of cross-linking; however, such gels were found to be significantly stiffer 
 31 
than natural vitreous. Further studies addressed at reducing this mismatch between the mechanical 
properties of PVA-MA and those of natural vitreous are needed to understand whether such a 
material remains a valid contender for vitreous substitution. 
 
6.3. A meeting point between the two approaches: a promise for the future 
 
As mentioned above, maybe the major limitation of the modified-natural polymers is their short 
residence time in the vitreous cavity and poor tamponade effect, which makes them unsuitable in 
the treatment of RD cases. The development of hyaluronic acid and gelatin hydrogels could provide 
a new class of substitutes combining a composition similar to that of the natural vitreous with 
appropriate physico-mechanical properties, degradation kinetics and tamponade ability. 
 
6.3.1. Cross-linked hyaluronic acid 
 
In the early 1990s, Balazs and co-workers developed the so-called “hylan gel”, obtained by cross-
linking sodium hyaluronate by divinyl sulphone or formaldehyde [190]. The gel, tested in rabbits 
and monkeys, was water-insoluble and biocompatible; however it could enter the sub-retinal space 
through retinal breaks due to its insufficient coherence.  
Very recently, promising results were achieved by Su et al. [191], who synthesized an hydrogel 
formed by oxidated hyaluronic acid cross-linked with adipic acid dihydrazide (ADH). The 
refractive index of the final hydrogel ranged within 1.3420-1.3442, which is quite similar to that of 
human vitreous. In vitro degradation tests showed that the hydrogel maintain the gel matrix over 35 
days, depending on the ADH concentration. Interestingly, the cytotoxicity was evaluated by using 
RPE cells and the materials was found to be non-toxic. In addition, the hydrogel was injected into 
the vitreous cavity of rabbits’ eyes: no adverse reactions were detected after 3 weeks. Further tests 
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on the mechanical properties of the gel are necessary, but these preliminary results make it an 
interesting candidate as a potential long-term vitreous substitute. 
 
6.3.2. Cross-linked gelatin 
 
In 2010, Lai investigated in detail the ocular biocompatibility of two chemically modified gelatin 
hydrogels [192]. These materials was proposed as aqueous humour substitutes and matrices for 
controlled drug delivery; potential application in the context of vitreous replacement may be also 
deemed. The gelatin base was cross-linked with glutaraldheyde (GTA) or 1-ethyl-3-(3-dimethyl 
aminopropyl)carbodiimide (EDAC); a significant inflammatory reaction was elicited by the 
presence of GTA-treated material, whereas the gelatin cross.linked with EDAC exhibited good 
biocompatibility and were well-tolerated without eliciting adverse effects. These preliminary results 
warrant further studies, particularly to assess the potential residence time of the gelatin hydrogel in 
the vitreous cavity. 
 
7. Hydrogels: the best candidates for vitreous substitution?  
 
The existing literature demonstrates that, ideally, optically transparent and biocompatible solutions 
of several polymers can be successfully used as short-term vitreous substitutes without inducing 
clinical postoperative complications in the patient’s eye. On the contrary, the search for a suitable 
biomaterial to be used as a long-term substitute is a more complex issue. Essentially, the major 
problem is to find an appropriate formulation that can be left in situ indefinitely without unwanted 
long-term side effects requiring the removal of the substitute. An ideal candidate as an artificial 
vitreous should closely mimic the light transmittance of the natural vitreous humour, as well as its 
physical and mechanical properties; most importantly, it should not change its features 
postoperatively. Polymeric hydrogels seem to be promising materials for long-term vitreous 
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replacement, as they generally show excellent transparency, are highly biocompatible and can act as 
viscoelatic shock-absorbing materials, thereby closely mimicking the behaviour of natural vitreous. 
By acting on the formulation and synthesis process of the hydrogel, the density and rigidity of the 
final vitreous substitute could be properly tailored in order to match those of natural vitreous. In 
addition, some experimentally tested hydrogels can gel after injection into the vitreous cavity, 
thereby avoiding gel fragmentation due to shear stresses during injection via small-gauge needles. 
An interesting approach to solve this dramatic problems was proposed very recently by Ravi and 
co-workers [169,173], who studied the in situ regelation of PAA gels. Finally, hydrogels might be 
used as smart matrices for controlled drug release within the vitreous cavity of patients suffering 
from serious intravitreal affections, such as PVR.  
At present, cross-linked PVA [184,185] and PAA [169,173] seem to be the most promising 
candidates as long-term vitreous substitutes, and, therefore, they are undoubtedly worthy of further 
investigation and experimentation in the next years.  
 
8. Criteria and guidelines for selecting suitable vitreous substitutes 
 
Over the years, many substances have been proposed as potential candidates for vitreous 
substitution but in most cases they were selected according to ambiguously defined criteria. In 
general, ease of injection and good optical transparency (before and after injection) have been 
considered the primary criteria of choice, but often no systematic investigation of the 
biocompatibility of the potential vitreous substitute, as well as of the injection-induced changes in 
its rheological properties has been carried out prior to in vivo tests. 
In the mid 1990s, Chirila et al. [187] in a study about PMAGME suggested for the first time the use 
of in vitro cytotoxicty test as an eliminatory criterion in the selection of polymers as potential 
vitreous substitutes; such tests are also useful because they avoid unnecessary animal experiments. 
Another important eliminatory criterion starts from the consideration that the natural vitreous body 
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possesses viscoelastic properties: therefore, a potential candidate for prolonged vitreous substitution 
should be viscoelastic and exhibit rheological properties similar to those of the natural vitreous. 
Under this viewpoint, cross-linked gels showed to be very suitable for vitreous replacement. 
However, a serious problems has to be considered: the shear stresses due to the procedure of 
polymer injection into the vitreous cavity causes a large deformation of the gel, that may exhibit 
physical properties different from those displayed before injection. A detailed study of Dalton et al. 
clearly demonstrated that a careful rheological analysis plays a crucial role in the selection of 
hydrogels as vitreous substitutes [165]. Specifically, the effect of the gel injection through small-
gauge needles should be investigated, since it can have detrimental consequences on the mechanical 
properties of the polymer. 
In the next years, it would be very useful to elaborate a standard and detailed protocol for selecting 
and testing the materials proposed as potential vitreous substitutes. Very recently, Leone et al. 
published a comprehensive and actually complete research work about the suitability of different 
cross-linked PVA hydrogels for vitreous replacement [185]. By taking this work as a starting point 
and on the basis of the suggestions provided over the years by other authors [27,165], it is possible 
to draft an ideal testing protocol that should include the following investigations before eventual in 
vivo experimentations:  
(i) light transmittance (for instance by UV-vis spectrophotometry);  
(ii) assessment of the kinetics of hydration, water uptake and swelling (for instance, by 
weight measurements); 
(iii) rheological measurements: oscillatory shear stress analysis, shear creep analysis and 
thixotropic properties (a rheometer is necessary for such analyses); 
(iv) assessment of the diffusion coefficient of a model solute (for instance by means of NMR 
spectroscopy, as done for the first time by Leone et al. in a pilot study [185]); 
(v) in vitro biocompatibility, cells proliferation and cells viability (the appropriate ISO 
standard should be followed [193]; the cell type for preliminary tests could be mouse 
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fibroblasts, as already done by Chirila et al. [165], Suri et al. [156], Leone et al. [185], 
or RPE cells as done by Su et al. [191]; 
(vi) evaluation of the possible degradation of the vitreous substitute during injection: ex vivo 
animal or human cadaver eyes could be used, as done by Ravi and co-workers 
[169,173].  
 
9. Conclusions 
 
The replacement of the vitreous body is a challenging but also complex issue of ophthalmic 
research. Although several and various substances have been proposed over the years as potential 
vitreous substitutes, at present only silicone oil is used in the clinical practice for long-term vitreous 
substitution, although it may induce several clinical complications. Gases are used as temporary 
vitreous substitutes, and PFCLs are recommended for intraoperative use only during vitrectomy 
procedures. The future of vitreous substitutes is to find an appropriate biomaterial that can be left in 
situ indefinitely without long-term complications. Primarily, an ideal artificial vitreous should 
mimic the light transmittance and the mechanical properties of the natural vitreous. Polymeric 
hydrogels seem to be promising materials for long-term vitreous replacement, as they exhibit 
excellent transparency, are highly biocompatible and can act as viscoelatic shock-absorbers, thereby 
closely mimicking the behaviour of the natural vitreous. By acting on the formulation and synthesis 
process of the hydrogels, the density and rigidity of the final vitreous substitute could be tailored in 
order to match those of natural vitreous. Furthermore, it has been demonstrated that some hydrogels 
can undergo in situ gelation after injection into the vitreous cavity, thereby avoiding unwanted 
injection-induced changes in the final gel. Eventually, hydrogels may be also used as matrices for 
intravitreal drug release. On the basis of studies performed in the literature up to now, cross-linked 
PVA and PAA seem to be the most promising candidates, but they were not yet approved for 
clinical use.  
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Another class of very attractive substances comprises SFAs and the so-called “heavy oils” 
(mixtures of silicone oil and SFAs), that in the last decade have been successfully experimented in 
the management of primary and persistent RRD cases with very good long-term clinical outcomes. 
Further studies about the potential and performances of these tamponade agents are currently in 
progress, but they are already marketed worldwide and used by several ophthalmic surgeons in the 
clinical practice.  
The development in the next years of a standard protocol for selecting and investigating potential 
vitreous substitutes would be very desirable, as it would be an useful tool for the researchers 
working on this topic. 
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Figure  
 
Fig. 1. The structure of the eye with its essential elements: 1 = cornea, 2 = anterior chamber, 3 = 
aqueous humour, 4 = pupil, 5 = iris, 6 = posterior chamber, 7 = crystalline lens, 8 = zonule, 9 = 
ciliary body, 10 = vitreous body, 11 = retina, 12 = macula, 13 = fovea, 14 = head of the optic nerve, 
15 = optic nerve, 16 = choroid, 17 = sclera, 18 = lateral rectus muscle, 19 = medial rectus muscle, 
20 = conjunctiva.  
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Fig. 2. Typical 3-port pars plana vitrectomy procedure: the aspiration pipe (the so-called 
“vitrector”) (1) allows the slow removal of the natural vitreous, the infusion pipe (2) is used to 
replace the vitreous with an appropriate substitute and the light pipe (3) is useful to surgeon for 
exploring the vitreous cavity and for examining the retina.  
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Fig. 3. Pneumatic retinopexy: (a) surgical procedures and (b) successful clinical outcomes.  
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Table 1 
Medical glossary (terms listed alphabetically). 
Term Explanation 
Age-related macular degeneration 
(AMD) 
Pathology usually affecting older adults and resulting in a loss of vision in 
the center of the visual field. AMD “dry” form results from the results 
from the atrophy of the retinal pigment epithelial; AMD “wet” form causes 
vision loss due to abnormal blood vessel growth below the macula. 
Cataract Clouding that develops in the crystalline lens or in its envelop, varying in 
degree from slight to complete opacity. It prevents clear vision and may 
require the surgical removal of the lens.  
Diabetic retinopathy Retinopathy caused by complications of diabetes mellitus. It progresses 
from mild non-proliferative abnormalities, characterized by increased 
vascular permeability, to proliferative diabetic retinopathy, featured by the 
growth of new blood vessels on the retina and posterior surface of the 
vitreous. Macular edema can develop at all stages of this retinopathy. 
Epiretinal membranes Scar tissue-like membranes that form over the macula; they may be 
involved in retinal detachment and other vitreoretinal diseases. 
Fibroblasts Cells located in the vitreous humour; they are involved in the synthesis of 
the constituents (collagens, glycosaminoglycans, glycoprotein and others) 
of the extracellular matrix. 
Fovea Small pit, located in the centre of the macula, containing the highest 
concentration of cone cells in the retina; it is responsible for central vision 
and visual acuity. 
Glaucoma Group of ocular diseases associated with increased intraocular pressure, 
thereby involving damage to the optic nerve. Glaucoma has been 
appropriately defined the “silent thief of sight”, as the loss of vision 
normally occurs gradually over a long period of time and is often 
recognized only when the disease is quite advanced. 
Hyalocytes Main cells located in the vitreous humour. Their role is not fully clear; 
they exhibit functional characteristics similar to those of macrophages and 
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are involved in maintaining the vitreous transparent and avascular.    
Intraocular pressure (IOP) Represents a measurement of the fluid pressure inside the eye (mean value 
in normal population ~15.5 mmHg). IOP above 21 mmHg indicates ocular 
hypertension, that may eventually develop into glaucoma. 
Macula Oval-shaped (~5 mm) highly pigmented yellow region near the centre of 
the retina in human eyes. 
Outer plexiform layer Retinal layer containing the axons of photoreceptors, together with 
horizontal cells dendrites and bipolar dendrites. 
Photoreceptors Sensing elements of the retina. They are divided in cones and rods, that are 
sensitive to different visual conditions since they contain two different 
light-sensitive proteins in their outer segment. 
Proliferative vitreoretinopathy 
(PVR) 
It involves the formation of scar tissue in the vitreous cavity; the so-
formed vitreoretinal membranes are a risk factor for tractional retinal 
detachment. 
Retinal pigment epithelium (RPE) Retinal layer firmly attached to the underlying choroid; it plays a key role 
in retinal physiology by forming the outer blood-retinal barrier and by 
supporting the function of the photoreceptors (cones and rods).  
Rhegmatogenous retinal 
detachment (RRD) 
Retinal detachment in which fluid from vitreous cavity enters the sub-
retinal space trough a full-thickness retinal break. 
Tractional retinal detachment 
(TRD) 
Retina detachment in which the retina is mechanically lifted up as a result 
of vitreoretinal tractions.  
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Table 2 
Overview of the main vitreous tamponade agents and substitutes used in the clinical practice (human patients). 
Year (first use) Substance Type
a
 Remarks References
b
 
1911 Air G Short residence time (few days); suitable for air/PFCL exchange [34-41] 
1912 Water L Short residence time [57,58] 
1948 Saline solutions L Short residence time; suitable for saline/PFCL exchange and for rinsing 
the vitreous cavity 
[59] 
1962 Silicone oil L Long-term vitreous substitute, with problems of oil toxicity mainly due to 
emulsification 
[21,60-92] 
1973 SF6 G Short residence time; cataract, problems due to IOP rise [42,46,47-
49,51] 
1980 C2F6, C4F8, C3F8 G More prolonged tamponade than SF6; cataract, problems due to IOP rise [43-48,50-54] 
1982 Xenon G Very short residence time (few hours) [55,56] 
1988 Perfluoro-n-octane, perfluorodecalin L Intraoperative use only is strongly recommended; it is usually the agent of 
choice 
[101-104,106-
111,115,118-
123] 
1990 Flurosilicone oil L Useful in the treatment of inferior RD; drawbacks analogous to those of 
silicone oil 
[92-97] 
1992 Perfluorotetradecahydrophenantrene L Intraoperative use only is strongly recommended [103,105.112,
116,117,122] 
 60 
2002 Perfluorohexyloctane L Good clinical outcomes; cataract; removal recommended after 2-3 months 
from operation 
[124,126-130] 
2003 Oxane HD
®
 L Adverse affects including emulsification, cataract, IOP rise [137-142] 
2005 Densiron-68
®
 L Good clinical outcomes; possible emulsification (oil removal after 3 
months from instillation is strongly recommended) 
[131-135,140-
142] 
2007 HW 46-3000 L Very good success rate in retinal reattachment; high rate of cataract 
formation; no inflammation and emulsification.  
[136] 
a
 G = gas; L = liquid. 
b 
References refer to numbering in the text. 
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Table 3 
Relevant physical properties of silicone-based oils (adapted from [60,92,94]).  
Oil RI (at RT) Density (g cm
-3
) Kinematic 
viscosity (cSt) 
Silicone oil 1.404 0.97 1000-12000 
Fluorosilicone oil 1.382 1.29 1000-10000 
Silicone/fluorosilicone 
copolymer oil 
1.387 1.16 170-200 
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Table 4 
Relevant physical properties of the most commonly used perfluorocarbon liquids (adapted from [92,122]).  
Perfluorocarbon liquid RI (at RT) Density (g cm
-3
) Kinematic 
viscosity (cSt) 
Perfluoro-n-octane 1.28 1.73 0.8 
Perfluorodecalin 1.31 1.93 2.7 
Perfluorotetradecahydroph
enantrene 
1.33 2.02 8.0 
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Table 5 
Relevant physical properties of the most commonly experimented heavy oils (adapted from [140,141]).  
Heavy oil Composition RI (at RT) Density (g cm
-3
) Kinematic 
viscosity (cSt) 
Oxane HD
®
 5700 cSt silicone oil 
+ RMN-3 (partially 
fluorinated olefin) 
1.40 1.02 ~3300 
Densiron-68
®
 5000 cSt silicone oil 
+ F6H8 
1.387 1.06 ~1500 
HW 46-3000 10
5
 cSt silicone oil + 
F4H6 
1.369 1.105 ~3100 
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Table 6 
Experimental polymers for vitreous substitution. 
Year (first use) Polymer Type
a
 Recipient
b
 Toxicity Persistence
c
 Remarks References
d
 
1954 Poly(1-vinyl-2-pyrrolidone) solutions SP A No ST  [159,160] 
1961 Hyaluronic acid solutions MNP H No ST  [145,146] 
1966 Polygeline MNP A, H No ST  [147,148] 
1966 Hyaluronate/collagen gel MNP A No ST  [153,155] 
1968 Polyacrylamide SP A No LT Promising physico-mechanical 
properties; possible gel 
degradation during injection 
[167-173] 
1968 Poly(glyceryl methacrylate) SP A No LT Traumatic implantation (dense 
pieces) or degradation during 
injection (gel). 
[174,175] 
1969 Collagen MNP A, H Yes ST Unsuitable [149-152] 
1971 Poly(2-hydroxyethyl methacrylate) SP A No LT Unsuitable (too traumatic 
implantation) 
[176] 
1984 Poly(2-hydroxyethyl acrylate) SP A Yes LT
 
 Unsuitable [177] 
1990 Hydroxypropyl methylcellulose SP A No ST  [178,179] 
1990 Pluronic F127 SP A Yes ST Unsuitable [181] 
1991 Poly(vinyl alcohol) hydrogels SP A No LT Good maintenance of physico-
mechanical properties 
[182-185] 
1992 Silicone gel SP A No LT Lacking of retinal tamponade 
effect 
[186] 
1993 Hyaluronic acid hydrogel MNP A No ST/LT Potential problems of gel 
coherence. Degradation time (> 
1 month) depending on the 
amount of cross-linking agent 
[190,191] 
1995  Poly(1-vinyl-2-pyrrolidone) hydrogels SP A No LT Possible gel degradation during 
injection 
[161-165] 
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1995 Poly(methyl 2-acrylamidoglycolate methyl ether) SP A Yes LT Unsuitable [187] 
1997 Methylated collagen MNP A No ST  [153,154] 
2000 Adcon
®
-L hydrogel SP A Yes ST Unsuitable [188] 
2004 Poly(vinyl alcohol methacrylate) SP IV No LT Significantly stiffer than natural 
vitreous 
[189] 
2006 Hyaluronic acid/gellan gum MNP IV No ST Insufficient mechanical 
properties 
[156] 
2010 Gelatin hydrogels MNP A No ST  [192] 
a
 MNP = modified natural polymers; SP = synthetic polymers. 
b
 A = animal; H = human; IV = in vitro only. 
c
 ST = short-term (due to resorption or degradation); LT = long-term. The ndication is given also in case of toxicity. 
d
 References refer to numbering in the test. 
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